Previous studies have found the BRAF T1799A mutation in approximately 45% of PTC and 25% of apparently PTC-derived anaplastic thyroid cancers, but not in follicular thyroid cancer (FTC) and benign thyroid tumors [77]. The gene discussed is BRAF; the disease is thyroid cancer, nonmedullary, 2.